Abstract
The emergence of SARS-CoV-2, leading to COVID-19, necessitated the development of new molecular and serological tests. Here, we describe a multiplexed serological assay developed as the global pandemic moved into New York State in the spring of 2020. The original microsphere immunoassay used a target antigen from the SARS-CoV-1 virus responsible for the 2003 SARS outbreak, but evolved to incorporate multiple SARS-CoV-2 protein antigens (nucleocapsid, spike and spike domains, spike and nucleocapsid proteins from seasonal human coronaviruses). Besides being highly versatile due to multiplex capabilities, the assay was highly specific and sensitive and adaptable to measuring both total antibodies and antibody isotypes. While determining the assay performance characteristics, we were able to identify antibody production patterns (e.g., kinetics of isotypes, individual variations) for total antibodies and individual antibody classes. Overall, the results provide insights into the laboratory response to new serology needs, and how the evolution and fine-tuning of a serology assay helped contribute to a better understanding of the antibody response to SARS-CoV-2.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was performed in part under a Project Award Agreement from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and financial assistance award 70NANB20H037 from the U.S. Department of Commerce, National Institute of Standards and Technology. Additional support was provided by a grant (P20-000271) from the New York Community Trust. A portion of the work described in this publication was supported by Cooperative Agreement Number NU50CK000516 from the Centers of Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All testing and archiving of human specimens were done under a declared New York State Public Health Emergency and also approved by New York State Department of Health Institutional Review Board (IRB 20-021).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data generated or analysed during this study are included in this submitted article (and its supplementary information files)
1Abbreviations
- COVID-19
- coronavirus disease 2019
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- HuCOV
- human endemic (seasonal) coronaviruses
- Ab
- antibody
- DIL
- Diagnostic Immunology Laboratory at the Wadsworth Center
- N
- nucleocapsid protein
- RBD
- receptor-binding domain
- MFI
- median fluorescent intensity
- FDA
- Food and Drug Administration
- EUA
- Emergency Use Authorization
- MIA
- microsphere immunoassay
